fluorouracil + interferon-α2b + mitomycin C + oxaliplatin

This is a combination chemotherapy regimen consisting of four agents—fluorouracil, interferon-α2b, mitomycin C, and oxaliplatin. Each drug has a distinct mechanism of action targeting cancer cells: - **Fluorouracil (5-FU)** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death in rapidly dividing cells. - **Interferon-α2b** is a recombinant cytokine with immunomodulatory and antiproliferative effects; it binds to the interferon alpha/beta receptor 2 (IFNAR2), activating immune responses against tumor cells[4]. - **Mitomycin C** is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription. - **Oxaliplatin** is a platinum-based alkylating agent that forms DNA crosslinks, preventing cell division and inducing apoptosis[5][7]. This combination has been explored in clinical studies for synergistic effects in various cancers. For example, combinations of fluorouracil with mitomycin C are used for anal, bladder, vulvar cancers[2], while regimens including oxaliplatin and fluorouracil are standard for colorectal cancer[5][7]. The addition of interferon-α2b may enhance antitumor activity through immune modulation[3]. This specific four-drug combination represents an investigational or experimental approach rather than a widely approved regimen.